HISAMITSU PHARMACEUTICAL CO., INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,752 JPY | -0.03% |
|
-0.08% | -12.97% |
Valuation
| Fiscal Period: February | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 393,394 | 542,719 | 296,969 | 303,688 | 293,429 | 275,257 | - | - |
| Enterprise Value (EV) 1 | 253,240 | 408,324 | 156,998 | 169,115 | 170,208 | 275,257 | 275,257 | 275,257 |
| P/E ratio | 21.2 x | 58.6 x | 30.8 x | 25.8 x | 21.3 x | 17.4 x | 16.8 x | 13.5 x |
| Yield | 1.72% | 1.26% | 2.3% | 2.21% | 2.19% | 2.4% | 2.45% | 2.5% |
| Capitalization / Revenue | 2.79 x | 4.74 x | 2.47 x | 2.37 x | 2.07 x | 1.8 x | 1.74 x | 1.66 x |
| EV / Revenue | 2.79 x | 4.74 x | 2.47 x | 2.37 x | 2.07 x | 1.8 x | 1.74 x | 1.66 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | 16.6 x | 316 x | 48.4 x | - | 47.9 x | 72.3 x | 19.3 x | 14.6 x |
| FCF Yield | 6.02% | 0.32% | 2.07% | - | 2.09% | 1.38% | 5.18% | 6.84% |
| Price to Book | 1.59 x | 2.15 x | 1.15 x | 1.16 x | 1.11 x | 1.06 x | 1.02 x | 0.97 x |
| Nbr of stocks (in thousands) | 81,364 | 81,735 | 81,139 | 79,499 | 75,743 | 73,343 | - | - |
| Reference price 2 | 4,835 | 6,640 | 3,660 | 3,820 | 3,874 | 3,753 | 3,753 | 3,753 |
| Announcement Date | 4/10/20 | 4/8/21 | 4/7/22 | 4/13/23 | 4/11/24 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: February | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 140,992 | 114,510 | 120,193 | 128,330 | 141,706 | 153,000 | 158,000 | 166,000 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | 22,727 | 10,671 | 9,337 | 11,599 | 13,167 | 15,900 | 18,500 | 23,700 |
| Operating Margin | 16.12% | 9.32% | 7.77% | 9.04% | 9.29% | 10.39% | 11.71% | 14.28% |
| Earnings before Tax (EBT) 1 | 26,155 | 12,197 | 12,956 | 16,113 | 19,186 | 22,300 | 22,900 | 28,100 |
| Net income 1 | 18,694 | 9,250 | 9,658 | 11,742 | 13,969 | 16,300 | 16,800 | 20,700 |
| Net margin | 13.26% | 8.08% | 8.04% | 9.15% | 9.86% | 10.65% | 10.63% | 12.47% |
| EPS 2 | 227.6 | 113.2 | 118.9 | 148.0 | 181.6 | 215.2 | 223.3 | 278.8 |
| Free Cash Flow 1 | 23,679 | 1,716 | 6,139 | - | 6,123 | 3,805 | 14,266 | 18,837 |
| FCF margin | 16.79% | 1.5% | 5.11% | - | 4.32% | 2.49% | 9.03% | 11.35% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | 126.67% | 18.55% | 63.56% | - | 43.83% | 23.34% | 84.92% | 91% |
| Dividend per Share 2 | 83.00 | 83.50 | 84.00 | 84.50 | 85.00 | 90.00 | 92.00 | 94.00 |
| Announcement Date | 4/10/20 | 4/8/21 | 4/7/22 | 4/13/23 | 4/11/24 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: February | 2021 S1 | 2022 S1 | 2022 Q3 | 2023 Q1 | 2023 S1 | 2023 Q3 | 2024 Q1 | 2024 S1 | 2024 Q3 | 2025 Q1 | 2025 S1 | 2026 Q1 | 2026 S1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 52,926 | 58,551 | 28,112 | 26,393 | 59,619 | 32,262 | 32,096 | 66,977 | 35,850 | 36,500 | 74,000 | 37,500 | 76,500 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 5,516 | 5,706 | 1,267 | 519 | 4,913 | 3,593 | 4,361 | 8,396 | 3,874 | 3,400 | 7,400 | 3,800 | 8,700 |
| Operating Margin | 10.42% | 9.75% | 4.51% | 1.97% | 8.24% | 11.14% | 13.59% | 12.54% | 10.81% | 9.32% | 10% | 10.13% | 11.37% |
| Earnings before Tax (EBT) 1 | 5,515 | 7,168 | 1,824 | 2,398 | 8,935 | 4,094 | 5,712 | 11,638 | 5,021 | 4,000 | 9,200 | 4,400 | 10,500 |
| Net income 1 | 3,693 | 5,002 | 1,216 | 1,631 | 6,504 | 3,018 | 4,049 | 8,417 | 3,693 | 3,300 | 7,500 | 3,200 | 7,600 |
| Net margin | 6.98% | 8.54% | 4.33% | 6.18% | 10.91% | 9.35% | 12.62% | 12.57% | 10.3% | 9.04% | 10.14% | 8.53% | 9.93% |
| EPS 2 | 45.22 | 61.20 | 14.94 | 20.46 | 81.58 | 37.88 | 52.09 | 108.3 | 48.30 | 43.60 | 91.30 | 42.50 | 93.00 |
| Dividend per Share | 41.75 | 42.00 | - | - | 42.25 | - | - | 42.50 | - | - | - | - | - |
| Announcement Date | 10/8/20 | 10/14/21 | 1/13/22 | 7/7/22 | 10/12/22 | 1/12/23 | 7/13/23 | 10/6/23 | 1/11/24 | - | - | - | - |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: February | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 140,154 | 134,395 | 139,971 | 134,573 | 123,221 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 23,679 | 1,716 | 6,139 | - | 6,123 | 3,805 | 14,266 | 18,837 |
| ROE (net income / shareholders' equity) | 7.5% | 3.7% | 3.8% | 4.7% | 5.4% | 6.1% | 6.2% | 7.4% |
| ROA (Net income/ Total Assets) | 8.47% | 3.05% | 4.19% | 5.2% | 6.11% | 6.1% | - | - |
| Assets 1 | 220,623 | 303,627 | 230,300 | 225,599 | 228,455 | 267,213 | - | - |
| Book Value Per Share 2 | 3,046 | 3,084 | 3,172 | 3,294 | 3,493 | 3,553 | 3,676 | 3,854 |
| Cash Flow per Share 2 | 279.0 | 163.0 | 172.0 | 210.0 | 248.0 | 221.0 | 269.0 | 335.0 |
| Capex 1 | 3,652 | 3,573 | 4,729 | 7,875 | 12,065 | 13,900 | 5,000 | 5,000 |
| Capex / Sales | 2.59% | 3.12% | 3.93% | 6.14% | 8.51% | 9.08% | 3.16% | 3.01% |
| Announcement Date | 4/10/20 | 4/8/21 | 4/7/22 | 4/13/23 | 4/11/24 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3,753
JPY
Average target price
3,950
JPY
Spread / Average Target
+5.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.97% | 1.7B | |
| +55.55% | 816B | |
| +41.67% | 634B | |
| -6.83% | 351B | |
| +17.15% | 323B | |
| +7.09% | 293B | |
| +14.04% | 238B | |
| +1.19% | 222B | |
| +13.55% | 218B | |
| +7.87% | 167B |
- Stock Market
- Equities
- 4530 Stock
- Financials Hisamitsu Pharmaceutical Co., Inc.
